Other clinicopathologic factors found to be associated with OS included nonendometrioid carcinoma (HR, 7.250; 95% CI, 2.669–19.693), FIGO grade 3 (HR, 3.678; 95% CI, 1.399–9.669), advanced stage (FIGO stages III–IV) (HR, 8.356; 95% CI, 3.212–21.740), lymph node metastasis (HR, 4.718; 95% CI, 1.728–12.882), and p53 mutant pattern (HR, 3.814; 95% CI, 1.401–10.379) (Table 4). This evidence concerns the gene TP53 and metastatic malignant neoplasm in the lymph nodes.